In a significant step toward improving everyday respiratory care, Zydus Lifesciences Limited has launched PepAir, India’s first affordable oscillating positive expiratory pressure (OPEP) device. Designed as a drug-free, handheld solution, PepAir aims to help patients manage chronic respiratory conditions such as COPD, asthma, and bronchiectasis more effectively.
With over 90 lakh people in India affected by these chronic lung diseases, the need for accessible airway clearance solutions has never been greater.
Chronic mucous hypersecretion is a common and persistent challenge among patients with COPD, asthma, and bronchiectasis. Excess mucus can obstruct airways, worsen coughing, and significantly impair breathing quality. While OPEP-based airway clearance therapy is recommended in established clinical guidelines, affordability has often limited patient access.
PepAir has been introduced to bridge this gap.
Priced at Rs. 990 per unit, the device is positioned as an accessible solution for everyday use—especially for patients who require long-term airway clearance therapy as part of routine disease management.
PepAir is an innovative OPEP device featuring a three-resistance system that allows patients to customise therapy intensity based on their needs. The device works by generating controlled pressure and vibrations during exhalation, which helps:
Its patented, translucent handheld design makes it easy to use and suitable for regular home-based therapy.
Unlike many respiratory interventions, PepAir offers a drug-free alternative, making it a valuable complementary therapy for patients already on medication regimens.
PepAir is being launched under an agreement with AeroDel Technology Innovations Pvt. Ltd., an Indian medical device company focused on simplifying inhalation therapy and pulmonary rehabilitation. The collaboration brings together device innovation and Zydus’ extensive respiratory market expertise to deliver a patient-centric solution.
Speaking on the launch, Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, emphasised the company’s commitment to accessible healthcare innovation. He noted that PepAir reflects Zydus’ approach to making everyday care more practical and affordable for patients managing chronic respiratory conditions.
India is witnessing a sharp rise in respiratory diseases due to:
These factors have intensified the burden on patients and healthcare systems alike, making preventive and supportive therapies increasingly important.
Zydus is already one of India’s leading respiratory care players, supported by a strong legacy in oral and inhalation therapies. The company leads the oral bronchodilator segment with Deriphyllin, one of India’s most prescribed methylxanthines.
Its broader inhalation portfolio spans:
With the launch of PepAir, Zydus expands beyond pharmacological interventions into device-based respiratory care—reinforcing its commitment to comprehensive, patient-centric solutions.
PepAir represents more than just a new device launch. It signals a shift toward integrated respiratory care—where affordability, ease of use, and guideline-backed therapy come together to support better disease management.
By making OPEP therapy more accessible, Zydus aims to empower millions of patients to take control of their respiratory health—one breath at a time.